The pharmacological study of hypoglycemic properties of the recombinant antagonist interleukin-1 receptor

Authors

  • I. P. Bukhtiyarova Donetsk National Medicinal University, Ukraine
  • K. G. Shchokina National University of Pharmacy, Ukraine
  • S. M. Drogovoz National University of Pharmacy, Ukraine
  • O. M. Ischenko Research Institute of Pure Biochemicals, Russian Federation

DOI:

https://doi.org/10.24959/cphj.15.1347

Keywords:

streptozotocin-induced diabetes with nicotinamide, hypoglycemic effect, raleukin, anakinra

Abstract

Diabetes mellitus (DM) is one of global medical and social problems of the XXI-th century and according to the WHO definition it is a non-infectious pandemic. Over the past 10 years the number of diabetic patients in Ukraine increased by more than 1.5 times, and is more than 1.3 million people. According to modern concepts of the pathogenesis of diabetes type II, pro-inflammatory cytokines, namely interleukin-1 (IL-1), play one of the leading roles in development of the disease. The paper presents the results of the experimental study of hypoglycemic properties of the original recombinant antagonist IL-1 receptor raleukin on the model of II type diabetes. It has been found that on the model of streptozotocin-induced diabetes in rats with nicotinamide raleukin revealed the antidiabetic properties, namely, showed the hypoglycemic action, inhibited development of hyperinsulinemia and the reduced signs of insulin resistance. By the hypoglycemic effect and influence on the HOMA-IR insulin resistance index raleukin is not inferior to reference drugs metformin and anakinra, by its effect on the level of insulin in the blood serum of the experimental animals raleukin is as good as metformin and does not differ significantly from anakinra. The results obtained confirm the important role of IL in development of type II diabetes and indicate that raleukin is a promising drug for further preclinical and clinical study in order to include it in the complex therapy of diabetes.

References

Балаболкин М.И., Клебанова Е.М., Креминская В.М. Лечение сахарного диабета и его осложнений. – М., 2005.  512 с.

Бухтіярова І.П. // Укр. біофармац. журн. – 2014. – №3 (32). – С. 50-54.

Дедов И.И. // Вестник Рос. академии мед. наук. – 2012. – №1. – С. 7-13.

Доклінічні дослідження лікарських засобів: Метод. рекоменд. / За ред. член-кор. НАМН України О.В.Стефанова. – К.: Авіценна, 2001. – 528 с.

Меньшиков В.В., Делекторская Л.Н., Золотницкая Р.П. и др. Лабораторные методы исследования в клинике: Справочник / Под ред. В.В.Меньшикова. – М.: Медицина, 1997. – 368 с.

Пат. на корисну модель 92304 U, МПК А 61 Р 3/10. Застосування антагоніста рецепторів інтерлейкіну-1 ралейкіну в терапії інсулінонезалежного цукрово-го діабету / І.П.Бухтіярова, С.М.Дроговоз, О.М.Іщенко. – № u 2014 02454. Заявл.: 12.03.2014. Опубл.: 11.08.2014. – Бюл. №15. – 6 с.

Полторак В.В., Горбенко Н.І., Іванова О.В., Горшунська М.Ю. // Ендокри-нол. – 2000. – Т. 5, №2. – С. 249-251.

Скибчик В.А., Гутор Я.Г., Войнович М.О. та ін. // Експериментальна та клі-нічна фізіол. та біохімія. – 2012. – №1. – С. 57-60.

Сунцов Ю.И., Болотская Л.Л., Маслова О.В. и др. // Сахарный диабет. – 2011. – №1. – С. 15-18.

Шумейко О.Г. Експериментальне обґрунтування застосування екстракту з мідії чорноморської (Mytilus galloprovincialis Lam.) у комплексній терапії цукрового діабету: Дис. … канд. мед. наук: 14.01.14 – ендокринологія. – Х., 2009.  153 с.

Börjesson A., Carlsson C. // J. Endocrinol. – 2007. – Vol. 192 (2). – P. 381-387.

Cnop M., Welsh N., Jonas J.C. et al. // Diabetes. – 2005. – Vol. 54, Suppl. 2. – P. S97-S107.

Lagathu C., Yvan-Charvet L., Bastard J.P. et al. // Diabetologia. – 2006. – №49. – Р. 2162-2173.

Larsen C.M., Faulenbach M., Ehses J.A. et al. // Diabetes Care. – 2009. – Vol. 32, №9. – P. 1663-1668.

Mandrup-Poulsen T., Bendtzen K., Dinarello C.A. et al. // J. Immunol. – 1987. – Vol. 139 (12). – P. 4077-4082.

Sandgerg J.O., Andersson A., Eizirik D.L. et al. // Biochem. Biophys. Res Com-mun. – 1994. – Vol. 202 (1). – P. 543-548.

Downloads

Published

2015-05-02

Issue

Vol. 19 No. 2 (2015)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2015 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).